Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
symbols : Bmy crawled time : 15:20 save search
Strategic Analysis of Global Oral Anticoagulants Market Size Projected to Reach USD 34.1 Billion by 2028, Predicts Facts & Factors
Published: 2023-04-05 (Crawled : 15:20) - prnewswire.com
SNYNF | News | $94.25 480
|
Health Technology
|
| O: 0.69%
H: 0.0%
C: 0.0%
JNJ | News | $148.515 -0.7% 4.3M
|
Health Technology
|
| O: 3.71%
H: 0.78%
C: 0.75%
BMY | $48.825 -0.34% 9.7M
|
Health Technology
|
| O: 0.8%
H: 1.07%
C: 0.52%
ABT | News | $106.96 -0.59% 2.6M
|
Health Technology
|
| O: -0.17%
H: 1.62%
C: 1.54%
SNY | News | $46.765 -1.94% 950K
|
Health Technology
|
| O: 1.58%
H: 0.0%
C: 0.0%
global market
Melanoma to be the Most Promising Indication for the PD-1/PDL-1 Inhibitor Therapies in the U.S. and EU-5 Region - Exclusive DeepTech M-A-PTM Analysis by BIS Research
Published: 2022-10-07 (Crawled : 15:20) - prnewswire.com
GLAXF | News | $19.54 2.6K
|
Health Technology
|
| O: 6.33%
H: 0.0%
C: 0.0%
GSK | News | $40.905 -0.81% 890K
|
Health Technology
|
| O: 0.63%
H: 0.76%
C: -0.26%
BMY | $48.825 -0.34% 9.7M
|
Health Technology
|
| O: 0.14%
H: 0.16%
C: -0.91%
RCUS 4 | $15.315 -1.19% 140K
|
Health Technology
|
| O: -1.93%
H: 0.53%
C: -5.94%
INCY | $51.76 0.21% 600K
|
Health Technology
|
| O: -0.72%
H: 0.38%
C: -1.04%
AGEN A | $7.34 13.62% 840K
|
Health Technology
|
| O: -1.78%
H: 1.45%
C: -2.55%
melanoma research
Antiviral Drugs Market is expected to grow at a steady pace by 2027 | CAGR: 3.4% | UnivDatos Market Insights
Published: 2022-05-30 (Crawled : 15:20) - prnewswire.com
GLAXF | News | $19.54 2.6K
|
Health Technology
| Email alert
Add to watchlist
JNJ | News | $148.515 -0.7% 4.3M
|
Health Technology
| Email alert
Add to watchlist
BMY | $48.825 -0.34% 9.7M
|
Health Technology
| Email alert
Add to watchlist
ABBV | News | $168.21 -0.78% 1.2M
|
Health Technology
| Email alert
Add to watchlist
GSK | News | $40.905 -0.81% 890K
|
Health Technology
| Email alert
Add to watchlist
antiviral expected market drug
Neoadjuvant Opdivo (nivolumab) with Chemotherapy Significantly Improves Event-Free Survival in Patients with Resectable Non-Small Cell Lung Cancer in Phase 3 CheckMate -816 Trial
Published: 2022-04-11 (Crawled : 15:20) - biospace.com/
BMY | $48.825 -0.34% 9.7M
|
Health Technology
|
| O: -0.09%
H: 0.55%
C: -1.54%
opdivo trial cancer phase 3 nivolumab
Gainers vs Losers
| 59% | 41% |
Top 10 Gainers
CZOO | $10.52 110.82% 10M
|
CSSE 4 | $0.3181 108.86% 170M
|
Consumer Services
BOF | $1.87 59.83% 100M
|
AMST | $3.1 55.0% 66M
|
Technology Services
LICN | $0.85 51.79% 13M
|
WIMI | $1.03 41.99% 15M
|
Technology Services
SKIL 4 | $8.045 40.89% 230K
|
Information
MULN | News | $3.805 39.38% 11M
|
Information
RILY | $30.01 38.17% 11M
|
Finance
MTC | $3.04 35.71% 6.7M
|
Technology Services
Your saved searches
Save your searches and get alerts when important news are released.